M.J. Millward
44 works · 1,089 citations · h-index 14
Top works
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
- Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
- Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer
- Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
- A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)
- Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival
- Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM)
- Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia–Pacific region
- A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer
- Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).
- Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
- Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
- Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer
- CARDIAC ARREST – A MANIFESTATION OF 5‐FLUOROURACIL CARDIOTOXICITY
- Metastatic Melanoma to the Testis Simulating Primary Seminoma
- A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer
- Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
- Pulmonary toxicity following MOPP chemotherapy
- 610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
- Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.